PURPOSE: Radiofrequency ablation (RFA) is an accepted treatment option for primary and metastatic liver tumors. As percutaneous RFA has some limitations, laparoscopic RFA (LRFA) has been used as a therapeutic alternative for the treatment of hepatic malignancies. METHODS: Between March 2006 and September 2009, thirty patients with hepatic malignancies that were contraindicated for resection or percutaneous RFA underwent LRFA. Indications for this procedure were hepatocellular carcinoma (HCC, 21 patients), metastatic liver tumor (8 patients) and intrahepatic cholangiocarcinoma (1 patient). RESULTS: Among the 30 patients who underwent LRFA, 5 patients underwent concomitant laparoscopic liver resection. Intraoperative laparoscopic ultrasound detected new malignant lesions in 4 patients (13.3%). A total of 46 lesions were ablated by LRFA. There was no postoperative mortality. The three-year overall survival rate was 83.7% for the HCC group and 64.3% for the metastatic group. CONCLUSION: LRFA for hepatic malignancies proved to be a safe and effective treatment. Also, this procedure is indicated for lesions that are not amenable to percutaneous RFA or liver resection.
PURPOSE: Radiofrequency ablation (RFA) is an accepted treatment option for primary and metastatic liver tumors. As percutaneous RFA has some limitations, laparoscopic RFA (LRFA) has been used as a therapeutic alternative for the treatment of hepatic malignancies. METHODS: Between March 2006 and September 2009, thirty patients with hepatic malignancies that were contraindicated for resection or percutaneous RFA underwent LRFA. Indications for this procedure were hepatocellular carcinoma (HCC, 21 patients), metastatic liver tumor (8 patients) and intrahepatic cholangiocarcinoma (1 patient). RESULTS: Among the 30 patients who underwent LRFA, 5 patients underwent concomitant laparoscopic liver resection. Intraoperative laparoscopic ultrasound detected new malignant lesions in 4 patients (13.3%). A total of 46 lesions were ablated by LRFA. There was no postoperative mortality. The three-year overall survival rate was 83.7% for the HCC group and 64.3% for the metastatic group. CONCLUSION: LRFA for hepatic malignancies proved to be a safe and effective treatment. Also, this procedure is indicated for lesions that are not amenable to percutaneous RFA or liver resection.
Authors: S A Curley; F Izzo; P Delrio; L M Ellis; J Granchi; P Vallone; F Fiore; S Pignata; B Daniele; F Cremona Journal: Ann Surg Date: 1999-07 Impact factor: 12.969
Authors: Richard J Bleicher; David P Allegra; Dean T Nora; Thomas F Wood; Leland J Foshag; Anton J Bilchik Journal: Ann Surg Oncol Date: 2003 Jan-Feb Impact factor: 5.344
Authors: Kyung Ho Kim; Yong Sik Yoon; Chang Sik Yu; Tae Won Kim; Hye Jin Kim; Pyo Nyun Kim; Hyun Kwon Ha; Jin Cheon Kim Journal: J Korean Surg Soc Date: 2011-07-11
Authors: Jung Yeon Lee; Young Hoon Kim; Young Hoon Roh; Kyung Bin Roh; Kwan Woo Kim; Sung Hwa Kang; Yang Hyun Baek; Sung Wook Lee; Sang Young Han; Hee Jin Kwon; Jin Han Cho Journal: Ann Surg Treat Res Date: 2016-02-26 Impact factor: 1.859